ID   APBB1_HUMAN             Reviewed;         710 AA.
AC   O00213; A1E379; A6NH82; A6NL69; B7Z1J5; B7Z1J6; B7Z2Y0; D3DQT2; Q7Z324;
AC   Q96A93; V9GYK0; V9GYT4;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 2.
DT   18-JUN-2025, entry version 215.
DE   RecName: Full=Amyloid beta precursor protein binding family B member 1 {ECO:0000312|HGNC:HGNC:581};
DE   AltName: Full=Amyloid-beta A4 precursor protein-binding family B member 1 {ECO:0000250|UniProtKB:Q9QXJ1};
DE   AltName: Full=Protein Fe65 {ECO:0000250|UniProtKB:Q9QXJ1};
GN   Name=APBB1 {ECO:0000312|HGNC:HGNC:581};
GN   Synonyms=FE65 {ECO:0000303|PubMed:8894693}, RIR
GN   {ECO:0000312|HGNC:HGNC:581};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8894693; DOI=10.1093/hmg/5.10.1589;
RA   Bressler S.L., Gray M.D., Sopher B.L., Hu Q., Hearn M.G., Pham D.G.,
RA   Dinulos M.B., Fukuchi K., Sisodia S.S., Miller M.A., Disteche C.M.,
RA   Martin G.M.;
RT   "cDNA cloning and chromosome mapping of the human Fe65 gene: interaction of
RT   the conserved cytoplasmic domains of the human beta-amyloid precursor
RT   protein and its homologues with the mouse Fe65 protein.";
RL   Hum. Mol. Genet. 5:1589-1598(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9799084; DOI=10.1007/s004390050820;
RA   Hu Q., Kukull W.A., Bressler S.L., Gray M.D., Cam J.A., Larson E.B.,
RA   Martin G.M., Deeb S.S.;
RT   "The human FE65 gene: genomic structure and an intronic biallelic
RT   polymorphism associated with sporadic dementia of the Alzheimer type.";
RL   Hum. Genet. 103:295-303(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=21824145; DOI=10.1111/j.1471-4159.2011.07420.x;
RA   Domingues S.C., Henriques A.G., Fardilha M., da Cruz E Silva E.F.,
RA   da Cruz E Silva O.A.;
RT   "Identification and characterization of a neuronal enriched novel
RT   transcript encoding the previously described p60Fe65 isoform.";
RL   J. Neurochem. 119:1086-1098(2011).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 4 AND 6).
RC   TISSUE=Caudate nucleus, and Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Fetal brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION, INTERACTION WITH ABL1, SUBCELLULAR LOCATION, PHOSPHORYLATION AT
RP   TYR-547 BY ABL1, AND MUTAGENESIS OF TYR-117; TYR-234; TYR-269; TYR-270;
RP   TYR-403; TYR-467; 269-TYR--TRP-271; TYR-546; TYR-547 AND TYR-658.
RX   PubMed=15031292; DOI=10.1074/jbc.m311479200;
RA   Perkinton M.S., Standen C.L., Lau K.F., Kesavapany S., Byers H.L., Ward M.,
RA   McLoughlin D.M., Miller C.C.;
RT   "The c-Abl tyrosine kinase phosphorylates the Fe65 adaptor protein to
RT   stimulate Fe65/amyloid precursor protein nuclear signaling.";
RL   J. Biol. Chem. 279:22084-22091(2004).
RN   [10]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH NEK6.
RX   PubMed=17512906; DOI=10.1016/j.bbrc.2007.04.203;
RA   Lee E.J., Hyun S.H., Chun J., Kang S.S.;
RT   "Human NIMA-related kinase 6 is one of the Fe65 WW domain binding
RT   proteins.";
RL   Biochem. Biophys. Res. Commun. 358:783-788(2007).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH APP.
RX   PubMed=18468999; DOI=10.1074/jbc.m801827200;
RA   Nakaya T., Kawai T., Suzuki T.;
RT   "Regulation of FE65 nuclear translocation and function by amyloid beta-
RT   protein precursor in osmotically stressed cells.";
RL   J. Biol. Chem. 283:19119-19131(2008).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-547, INTERACTION
RP   WITH RASD1, AND MUTAGENESIS OF TYR-547.
RX   PubMed=18922798; DOI=10.1074/jbc.m801874200;
RA   Lau K.-F., Chan W.-M., Perkinton M.S., Tudor E.L., Chang R.C.C.,
RA   Chan H.-Y., McLoughlin D.M., Miller C.C.J.;
RT   "Dexras1 interacts with FE65 to regulate FE65-amyloid precursor protein-
RT   dependent transcription.";
RL   J. Biol. Chem. 283:34728-34737(2008).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH H2AX AND MAPK8.
RX   PubMed=19234442; DOI=10.1038/nature07849;
RA   Cook P.J., Ju B.G., Telese F., Wang X., Glass C.K., Rosenfeld M.G.;
RT   "Tyrosine dephosphorylation of H2AX modulates apoptosis and survival
RT   decisions.";
RL   Nature 458:591-596(2009).
RN   [14]
RP   FUNCTION, INTERACTION WITH SET AND TSHZ3, IDENTIFICATION IN A TRIMERIC
RP   COMPLEX WITH HDAC1 AND TSHZ3, CHROMATIN-BINDING, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=19343227; DOI=10.1371/journal.pone.0005071;
RA   Kajiwara Y., Akram A., Katsel P., Haroutunian V., Schmeidler J.,
RA   Beecham G., Haines J.L., Pericak-Vance M.A., Buxbaum J.D.;
RT   "FE65 binds Teashirt, inhibiting expression of the primate-specific
RT   caspase-4.";
RL   PLoS ONE 4:E5071-E5071(2009).
RN   [15]
RP   INTERACTION WITH RNF157, UBIQUITINATION BY RNF157, AND FUNCTION.
RX   PubMed=25342469; DOI=10.1038/cdd.2014.163;
RA   Matz A., Lee S.J., Schwedhelm-Domeyer N., Zanini D., Holubowska A.,
RA   Kannan M., Farnworth M., Jahn O., Goepfert M.C., Stegmueller J.;
RT   "Regulation of neuronal survival and morphology by the E3 ubiquitin ligase
RT   RNF157.";
RL   Cell Death Differ. 22:626-642(2015).
RN   [16]
RP   FUNCTION, INTERACTION WITH KAT5, ACETYLATION AT LYS-204 AND LYS-701, AND
RP   MUTAGENESIS OF LYS-204 AND LYS-701.
RX   PubMed=33938178; DOI=10.1515/hsz-2020-0279;
RA   Probst S., Riese F., Kaegi L., Krueger M., Russi N., Nitsch R.M.,
RA   Konietzko U.;
RT   "Lysine acetyltransferase Tip60 acetylates the APP adaptor Fe65 to increase
RT   its transcriptional activity.";
RL   Biol. Chem. 402:481-499(2021).
RN   [17]
RP   FUNCTION, INTERACTION WITH ARF6, MUTAGENESIS OF SER-459, AND
RP   PHOSPHORYLATION AT SER-459.
RX   PubMed=36250347; DOI=10.1096/fj.202200757r;
RA   Chau D.D., Li W., Chan W.W.R., Sun J.K., Zhai Y., Chow H.M., Lau K.F.;
RT   "Insulin stimulates atypical protein kinase C-mediated phosphorylation of
RT   the neuronal adaptor FE65 to potentiate neurite outgrowth by activating
RT   ARF6-Rac1 signaling.";
RL   FASEB J. 36:e22594-e22594(2022).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.33 ANGSTROMS) OF 253-289 IN COMPLEX WITH ENAH.
RX   PubMed=17686488; DOI=10.1016/j.jmb.2007.06.064;
RA   Meiyappan M., Birrane G., Ladias J.A.A.;
RT   "Structural basis for polyproline recognition by the FE65 WW domain.";
RL   J. Mol. Biol. 372:970-980(2007).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 534-667 IN COMPLEX WITH APP.
RX   PubMed=18833287; DOI=10.1038/embor.2008.188;
RA   Radzimanowski J., Simon B., Sattler M., Beyreuther K., Sinning I., Wild K.;
RT   "Structure of the intracellular domain of the amyloid precursor protein in
RT   complex with Fe65-PTB2.";
RL   EMBO Rep. 9:1134-1140(2008).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 366-505.
RX   PubMed=18550529; DOI=10.1074/jbc.m800861200;
RA   Radzimanowski J., Ravaud S., Schlesinger S., Koch J., Beyreuther K.,
RA   Sinning I., Wild K.;
RT   "Crystal structure of the human Fe65-PTB1 domain.";
RL   J. Biol. Chem. 283:23113-23120(2008).
CC   -!- FUNCTION: Transcription coregulator that can have both coactivator and
CC       corepressor functions (PubMed:15031292, PubMed:18468999,
CC       PubMed:18922798, PubMed:25342469, PubMed:33938178). Adapter protein
CC       that forms a transcriptionally active complex with the gamma-secretase-
CC       derived amyloid precursor protein (APP) intracellular domain
CC       (PubMed:15031292, PubMed:18468999, PubMed:18922798, PubMed:25342469).
CC       Plays a central role in the response to DNA damage by translocating to
CC       the nucleus and inducing apoptosis (PubMed:15031292, PubMed:18468999,
CC       PubMed:18922798, PubMed:25342469). May act by specifically recognizing
CC       and binding histone H2AX phosphorylated on 'Tyr-142' (H2AXY142ph) at
CC       double-strand breaks (DSBs), recruiting other pro-apoptosis factors
CC       such as MAPK8/JNK1 (PubMed:19234442). Required for histone H4
CC       acetylation at double-strand breaks (DSBs) (PubMed:19234442). Its
CC       ability to specifically bind modified histones and chromatin modifying
CC       enzymes such as KAT5/TIP60, probably explains its transcription
CC       activation activity (PubMed:33938178). Functions in association with
CC       TSHZ3, SET and HDAC factors as a transcriptional repressor, that
CC       inhibits the expression of CASP4 (PubMed:19343227). Associates with
CC       chromatin in a region surrounding the CASP4 transcriptional start
CC       site(s) (PubMed:19343227). Involved in hippocampal neurite branching
CC       and neuromuscular junction formation, as a result plays a role in
CC       spatial memory functioning (By similarity). Plays a role in the
CC       maintenance of lens transparency (By similarity). May play a role in
CC       muscle cell strength (By similarity). Acts as a molecular adapter that
CC       functions in neurite outgrowth by activating the RAC1-ARF6 axis upon
CC       insulin treatment (PubMed:36250347). {ECO:0000250|UniProtKB:Q9QXJ1,
CC       ECO:0000269|PubMed:15031292, ECO:0000269|PubMed:18468999,
CC       ECO:0000269|PubMed:18922798, ECO:0000269|PubMed:19234442,
CC       ECO:0000269|PubMed:19343227, ECO:0000269|PubMed:25342469,
CC       ECO:0000269|PubMed:33938178, ECO:0000269|PubMed:36250347}.
CC   -!- SUBUNIT: Component of a complex, at least composed of APBB1,
CC       RASD1/DEXRAS1 and APP (PubMed:18468999, PubMed:18833287,
CC       PubMed:18922798). Interacts (via PID domain 2) with APP (with the
CC       intracellular domain of the amyloid-beta precursor protein)
CC       (PubMed:18468999, PubMed:18833287). Interacts (via PID domain 2) with
CC       RASD1/DEXRAS1; impairs the transcription activation activity
CC       (PubMed:18922798). Interacts (via PID domain 1) with KAT5/TIP60
CC       (PubMed:33938178). Interacts (via the WW domain) with the proline-rich
CC       region of APBB1IP (By similarity). Interacts with TSHZ1 and TSHZ2 (By
CC       similarity). Interacts (via the WW domain) with histone H2AX (when
CC       phosphorylated on 'Tyr-142') and the proline-rich region of ENAH
CC       (PubMed:17686488). Interacts with MAPK8 (PubMed:19234442). Interacts
CC       (via PID domain 1) with TSHZ3 (via homeobox domain) (PubMed:19343227).
CC       Interacts with SET (PubMed:19343227). Found in a trimeric complex with
CC       HDAC1 and TSHZ3; the interaction between HDAC1 and APBB1 is mediated by
CC       TSHZ3 (PubMed:19343227). Interacts (via WWW domain) with NEK6
CC       (PubMed:17512906). Interacts (via WWW domain) with ABL1
CC       (PubMed:15031292). Interacts with RNF157 (PubMed:25342469). Interacts
CC       with ARF6 (PubMed:36250347). {ECO:0000250|UniProtKB:Q9QXJ1,
CC       ECO:0000269|PubMed:15031292, ECO:0000269|PubMed:17512906,
CC       ECO:0000269|PubMed:17686488, ECO:0000269|PubMed:18468999,
CC       ECO:0000269|PubMed:18833287, ECO:0000269|PubMed:18922798,
CC       ECO:0000269|PubMed:19234442, ECO:0000269|PubMed:19343227,
CC       ECO:0000269|PubMed:25342469, ECO:0000269|PubMed:33938178,
CC       ECO:0000269|PubMed:36250347}.
CC   -!- INTERACTION:
CC       O00213; Q06481: APLP2; NbExp=3; IntAct=EBI-81694, EBI-79306;
CC       O00213; P05067: APP; NbExp=10; IntAct=EBI-81694, EBI-77613;
CC       O00213; P05067-4: APP; NbExp=5; IntAct=EBI-81694, EBI-302641;
CC       O00213; P62330: ARF6; NbExp=9; IntAct=EBI-81694, EBI-638181;
CC       O00213; P00533: EGFR; NbExp=4; IntAct=EBI-81694, EBI-297353;
CC       O00213; P04626: ERBB2; NbExp=2; IntAct=EBI-81694, EBI-641062;
CC       O00213; Q07954: LRP1; NbExp=4; IntAct=EBI-81694, EBI-1046087;
CC       O00213; Q02563: Sv2a; Xeno; NbExp=3; IntAct=EBI-81694, EBI-466194;
CC       O00213-2; P05067: APP; NbExp=6; IntAct=EBI-13307975, EBI-77613;
CC       O00213-2; Q86YB2: DHX8; NbExp=3; IntAct=EBI-13307975, EBI-14405236;
CC       O00213-2; Q8NFZ0: FBH1; NbExp=3; IntAct=EBI-13307975, EBI-724767;
CC       O00213-2; Q92993: KAT5; NbExp=3; IntAct=EBI-13307975, EBI-399080;
CC       O00213-2; O15116: LSM1; NbExp=3; IntAct=EBI-13307975, EBI-347619;
CC       O00213-2; Q14141: SEPTIN6; NbExp=3; IntAct=EBI-13307975, EBI-745901;
CC       O00213-2; Q99720-4: SIGMAR1; NbExp=3; IntAct=EBI-13307975, EBI-25831036;
CC       O00213-2; O95416: SOX14; NbExp=3; IntAct=EBI-13307975, EBI-9087806;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18468999}.
CC       Cytoplasm {ECO:0000269|PubMed:18468999}. Nucleus
CC       {ECO:0000269|PubMed:15031292, ECO:0000269|PubMed:18468999,
CC       ECO:0000269|PubMed:18922798, ECO:0000269|PubMed:19343227}. Cell
CC       projection, growth cone {ECO:0000250|UniProtKB:P46933}. Nucleus speckle
CC       {ECO:0000269|PubMed:17512906}. Note=Colocalizes with TSHZ3 in axonal
CC       growth cone (By similarity). Colocalizes with TSHZ3 in the nucleus
CC       (PubMed:19343227). In normal conditions, it mainly localizes to the
CC       cytoplasm, while a small fraction is tethered to the cell membrane via
CC       its interaction with APP (PubMed:18468999). Following exposure to DNA
CC       damaging agents, it is released from cell membrane and translocates to
CC       the nucleus (PubMed:18468999). Nuclear translocation is under the
CC       regulation of APP (PubMed:18468999). Colocalizes with NEK6 at the
CC       nuclear speckles (PubMed:17512906). Phosphorylation at Ser-610 by SGK1
CC       promotes its localization to the nucleus (By similarity).
CC       {ECO:0000250|UniProtKB:P46933, ECO:0000269|PubMed:17512906,
CC       ECO:0000269|PubMed:18468999, ECO:0000269|PubMed:19343227}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1;
CC         IsoId=O00213-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O00213-2; Sequence=VSP_011658;
CC       Name=3;
CC         IsoId=O00213-3; Sequence=VSP_045326, VSP_045327, VSP_011658;
CC       Name=4; Synonyms=p60Fe65;
CC         IsoId=O00213-4; Sequence=VSP_047459;
CC       Name=5;
CC         IsoId=O00213-5; Sequence=VSP_045326, VSP_045327;
CC       Name=6;
CC         IsoId=O00213-6; Sequence=VSP_054709;
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain; strongly reduced in
CC       post-mortem elderly subjects with Alzheimer disease.
CC       {ECO:0000269|PubMed:19343227}.
CC   -!- TISSUE SPECIFICITY: [Isoform 4]: Expressed preferentially in the brain.
CC       {ECO:0000269|PubMed:21824145}.
CC   -!- PTM: Phosphorylation at Ser-610 by SGK1 promotes its localization to
CC       the nucleus (By similarity). Phosphorylated following nuclear
CC       translocation (PubMed:15031292, PubMed:18922798). Phosphorylation at
CC       Tyr-547 by ABL1 enhances transcriptional activation activity and
CC       reduces the affinity for RASD1/DEXRAS1 (PubMed:15031292,
CC       PubMed:18922798). Phosphorylated at Ser-459 by PKC upon insulin
CC       activation (PubMed:36250347). {ECO:0000250|UniProtKB:P46933,
CC       ECO:0000269|PubMed:15031292, ECO:0000269|PubMed:18922798,
CC       ECO:0000269|PubMed:36250347}.
CC   -!- PTM: Acetylation at Lys-204 and Lys-701 by KAT5 promotes its
CC       transcription activator activity. {ECO:0000269|PubMed:33938178}.
CC   -!- PTM: Polyubiquitination by RNF157 leads to degradation by the
CC       proteasome (PubMed:25342469). {ECO:0000269|PubMed:25342469}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD98057.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L77864; AAB93631.1; -; mRNA.
DR   EMBL; AF029234; AAC79942.1; -; Genomic_DNA.
DR   EMBL; AF047835; AAC79942.1; JOINED; Genomic_DNA.
DR   EMBL; EF103274; ABL07489.3; -; mRNA.
DR   EMBL; AK293550; BAH11531.1; -; mRNA.
DR   EMBL; AK293554; BAH11532.1; -; mRNA.
DR   EMBL; AK293643; BAH11554.1; -; mRNA.
DR   EMBL; AK295241; BAH12016.1; -; mRNA.
DR   EMBL; BX538185; CAD98057.1; ALT_INIT; mRNA.
DR   EMBL; AC068733; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC084337; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW68723.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68724.1; -; Genomic_DNA.
DR   EMBL; BC010854; AAH10854.1; -; mRNA.
DR   CCDS; CCDS31410.1; -. [O00213-2]
DR   CCDS; CCDS58114.1; -. [O00213-3]
DR   CCDS; CCDS66015.1; -. [O00213-4]
DR   CCDS; CCDS66016.1; -. [O00213-6]
DR   CCDS; CCDS66017.1; -. [O00213-5]
DR   CCDS; CCDS66018.1; -. [O00213-1]
DR   RefSeq; NP_001155.1; NM_001164.5. [O00213-1]
DR   RefSeq; NP_001244248.1; NM_001257319.3. [O00213-5]
DR   RefSeq; NP_001244249.1; NM_001257320.2. [O00213-4]
DR   RefSeq; NP_001244250.1; NM_001257321.2. [O00213-4]
DR   RefSeq; NP_001244252.1; NM_001257323.3. [O00213-3]
DR   RefSeq; NP_001244254.1; NM_001257325.3. [O00213-6]
DR   RefSeq; NP_001244255.1; NM_001257326.2. [O00213-4]
DR   RefSeq; NP_663722.1; NM_145689.3. [O00213-2]
DR   RefSeq; XP_011518342.1; XM_011520040.2.
DR   RefSeq; XP_016873130.1; XM_017017641.1.
DR   PDB; 2E45; NMR; -; A=241-290.
DR   PDB; 2HO2; X-ray; 1.33 A; A=253-289.
DR   PDB; 2IDH; X-ray; 2.28 A; A/B/C/D/E/F/G/H=253-289.
DR   PDB; 2OEI; X-ray; 1.35 A; A=253-289.
DR   PDB; 3D8D; X-ray; 2.20 A; A/B=366-505.
DR   PDB; 3D8E; X-ray; 2.80 A; A/B/C/D=366-505.
DR   PDB; 3D8F; X-ray; 2.70 A; A/B/C/D=366-505.
DR   PDB; 3DXC; X-ray; 2.10 A; A/C=534-667.
DR   PDB; 3DXD; X-ray; 2.20 A; A/C=534-667.
DR   PDB; 3DXE; X-ray; 2.00 A; A/C=534-667.
DR   PDB; 5NQH; X-ray; 2.60 A; A/B/C/D=534-667.
DR   PDBsum; 2E45; -.
DR   PDBsum; 2HO2; -.
DR   PDBsum; 2IDH; -.
DR   PDBsum; 2OEI; -.
DR   PDBsum; 3D8D; -.
DR   PDBsum; 3D8E; -.
DR   PDBsum; 3D8F; -.
DR   PDBsum; 3DXC; -.
DR   PDBsum; 3DXD; -.
DR   PDBsum; 3DXE; -.
DR   PDBsum; 5NQH; -.
DR   AlphaFoldDB; O00213; -.
DR   BMRB; O00213; -.
DR   SMR; O00213; -.
DR   BioGRID; 106819; 194.
DR   CORUM; O00213; -.
DR   DIP; DIP-30903N; -.
DR   ELM; O00213; -.
DR   FunCoup; O00213; 944.
DR   IntAct; O00213; 187.
DR   MINT; O00213; -.
DR   STRING; 9606.ENSP00000477213; -.
DR   GlyCosmos; O00213; 1 site, 1 glycan.
DR   GlyGen; O00213; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O00213; -.
DR   PhosphoSitePlus; O00213; -.
DR   BioMuta; APBB1; -.
DR   jPOST; O00213; -.
DR   MassIVE; O00213; -.
DR   PaxDb; 9606-ENSP00000477213; -.
DR   PeptideAtlas; O00213; -.
DR   ProteomicsDB; 47783; -. [O00213-1]
DR   ProteomicsDB; 47784; -. [O00213-2]
DR   ProteomicsDB; 6474; -.
DR   Pumba; O00213; -.
DR   Antibodypedia; 23808; 405 antibodies from 38 providers.
DR   DNASU; 322; -.
DR   Ensembl; ENST00000299402.10; ENSP00000299402.6; ENSG00000166313.20. [O00213-2]
DR   Ensembl; ENST00000311051.7; ENSP00000311912.3; ENSG00000166313.20. [O00213-2]
DR   Ensembl; ENST00000530885.5; ENSP00000433338.1; ENSG00000166313.20. [O00213-3]
DR   Ensembl; ENST00000608394.5; ENSP00000476442.1; ENSG00000166313.20. [O00213-4]
DR   Ensembl; ENST00000608645.5; ENSP00000476646.1; ENSG00000166313.20. [O00213-4]
DR   Ensembl; ENST00000608655.6; ENSP00000476846.1; ENSG00000166313.20. [O00213-5]
DR   Ensembl; ENST00000608704.5; ENSP00000476871.1; ENSG00000166313.20. [O00213-4]
DR   Ensembl; ENST00000609331.5; ENSP00000477069.1; ENSG00000166313.20. [O00213-6]
DR   Ensembl; ENST00000609360.6; ENSP00000477213.1; ENSG00000166313.20. [O00213-1]
DR   GeneID; 322; -.
DR   KEGG; hsa:322; -.
DR   MANE-Select; ENST00000609360.6; ENSP00000477213.1; NM_001164.5; NP_001155.1.
DR   UCSC; uc001mdb.4; human. [O00213-1]
DR   AGR; HGNC:581; -.
DR   CTD; 322; -.
DR   DisGeNET; 322; -.
DR   GeneCards; APBB1; -.
DR   HGNC; HGNC:581; APBB1.
DR   HPA; ENSG00000166313; Tissue enhanced (brain).
DR   MalaCards; APBB1; -.
DR   MIM; 602709; gene.
DR   OpenTargets; ENSG00000166313; -.
DR   VEuPathDB; HostDB:ENSG00000166313; -.
DR   eggNOG; ENOG502QT08; Eukaryota.
DR   GeneTree; ENSGT00390000000002; -.
DR   HOGENOM; CLU_021196_0_0_1; -.
DR   InParanoid; O00213; -.
DR   OMA; ENHQDQD; -.
DR   OrthoDB; 5969782at2759; -.
DR   PAN-GO; O00213; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; O00213; -.
DR   PathwayCommons; O00213; -.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   SignaLink; O00213; -.
DR   SIGNOR; O00213; -.
DR   BioGRID-ORCS; 322; 8 hits in 1157 CRISPR screens.
DR   ChiTaRS; APBB1; human.
DR   EvolutionaryTrace; O00213; -.
DR   GeneWiki; APBB1; -.
DR   GenomeRNAi; 322; -.
DR   Pharos; O00213; Tbio.
DR   PRO; PR:O00213; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; O00213; protein.
DR   Bgee; ENSG00000166313; Expressed in right hemisphere of cerebellum and 162 other cell types or tissues.
DR   ExpressionAtlas; O00213; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0030426; C:growth cone; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0045202; C:synapse; IDA:UniProtKB.
DR   GO; GO:0001540; F:amyloid-beta binding; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IPI:UniProtKB.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; TAS:ARUK-UCL.
DR   GO; GO:0060090; F:molecular adaptor activity; IDA:UniProt.
DR   GO; GO:0070064; F:proline-rich region binding; IPI:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; TAS:ARUK-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007409; P:axonogenesis; NAS:UniProtKB.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0006974; P:DNA damage response; IDA:UniProtKB.
DR   GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IGI:ARUK-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:UniProt.
DR   GO; GO:0050714; P:positive regulation of protein secretion; TAS:ARUK-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; TAS:ARUK-UCL.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   GO; GO:0006939; P:smooth muscle contraction; ISS:UniProtKB.
DR   CDD; cd01272; PTB1_Fe65; 1.
DR   CDD; cd01271; PTB2_Fe65; 1.
DR   CDD; cd00201; WW; 1.
DR   FunFam; 2.30.29.30:FF:000019; Amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65); 1.
DR   FunFam; 2.20.70.10:FF:000003; amyloid beta A4 precursor protein-binding family B member 2; 1.
DR   FunFam; 2.30.29.30:FF:000034; amyloid beta A4 precursor protein-binding family B member 2; 1.
DR   Gene3D; 2.20.70.10; -; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 2.
DR   InterPro; IPR039576; APBB1/2/3.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR006020; PTB/PI_dom.
DR   InterPro; IPR001202; WW_dom.
DR   InterPro; IPR036020; WW_dom_sf.
DR   PANTHER; PTHR14058; AMYLOID BETA A4 PRECURSOR PROTEIN-BINDING FAMILY B; 1.
DR   PANTHER; PTHR14058:SF5; AMYLOID BETA PRECURSOR PROTEIN BINDING FAMILY B MEMBER 1; 1.
DR   Pfam; PF00640; PID; 2.
DR   Pfam; PF00397; WW; 1.
DR   SMART; SM00462; PTB; 2.
DR   SMART; SM00456; WW; 1.
DR   SUPFAM; SSF50729; PH domain-like; 2.
DR   SUPFAM; SSF51045; WW domain; 1.
DR   PROSITE; PS01179; PID; 2.
DR   PROSITE; PS01159; WW_DOMAIN_1; 1.
DR   PROSITE; PS50020; WW_DOMAIN_2; 1.
DR   neXtProt; NX_O00213; -.
DR   PharmGKB; PA24873; -.
DR   TreeFam; TF314331; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Apoptosis;
KW   Cell membrane; Cell projection; Chromatin regulator; Cytoplasm; DNA damage;
KW   Membrane; Nucleus; Phosphoprotein; Proteomics identification;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..710
FT                   /note="Amyloid beta precursor protein binding family B
FT                   member 1"
FT                   /id="PRO_0000076049"
FT   DOMAIN          253..285
FT                   /note="WW"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00224"
FT   DOMAIN          370..509
FT                   /note="PID 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00148"
FT   DOMAIN          542..699
FT                   /note="PID 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00148"
FT   REGION          1..24
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          131..254
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          276..299
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          340..365
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..15
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        145..173
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        223..234
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        287..299
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         204
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:33938178"
FT   MOD_RES         459
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000269|PubMed:36250347"
FT   MOD_RES         517
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QXJ1"
FT   MOD_RES         547
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000269|PubMed:15031292,
FT                   ECO:0000269|PubMed:18922798"
FT   MOD_RES         610
FT                   /note="Phosphoserine; by SGK1"
FT                   /evidence="ECO:0000250|UniProtKB:P46933"
FT   MOD_RES         701
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:33938178"
FT   VAR_SEQ         1..259
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:21824145"
FT                   /id="VSP_047459"
FT   VAR_SEQ         1..240
FT                   /note="MSVPSSLSQSAINANSHGGPALSLPLPLHAAHNQLLNAKLQATAVGPKDLRS
FT                   AMGEGGGPEPGPANAKWLKEGQNQLRRAATAHRDQNRNVTLTLAEEASQEPEMAPLGPK
FT                   GLIHLYSELELSAHNAANRGLRGPGLIISTQEQGPDEGEEKAAGEAEEEEEDDDDEEEE
FT                   EDLSSPPGLPEPLESVEAPPRPQALTDGPREHSKSASLLFGMRNSAASDEDSSWATLSQ
FT                   GSPSYGSPEDT -> MTQMR (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054709"
FT   VAR_SEQ         1..213
FT                   /note="Missing (in isoform 3 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_045326"
FT   VAR_SEQ         214..240
FT                   /note="NSAASDEDSSWATLSQGSPSYGSPEDT -> MSAMFSQDFFLAIILQDSSA
FT                   (in isoform 3 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_045327"
FT   VAR_SEQ         462..463
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_011658"
FT   VARIANT         327
FT                   /note="M -> V (in dbSNP:rs1800423)"
FT                   /id="VAR_014444"
FT   VARIANT         396
FT                   /note="N -> S (in dbSNP:rs1800425)"
FT                   /id="VAR_014445"
FT   MUTAGEN         117
FT                   /note="Y->F: No effect on phosphorylation by ABL1."
FT                   /evidence="ECO:0000269|PubMed:15031292"
FT   MUTAGEN         204
FT                   /note="K->Q: Mimics acetylation; leading to increased
FT                   transcription activator activity; when associated with
FT                   Q-701."
FT                   /evidence="ECO:0000269|PubMed:33938178"
FT   MUTAGEN         204
FT                   /note="K->R: Abolished acetylation by KAT5, leading to
FT                   decreased transcription activator activity; when associated
FT                   with R-701."
FT                   /evidence="ECO:0000269|PubMed:33938178"
FT   MUTAGEN         234
FT                   /note="Y->F: No effect on phosphorylation by ABL1."
FT                   /evidence="ECO:0000269|PubMed:15031292"
FT   MUTAGEN         269..271
FT                   /note="YYW->AAA: Impairs transcriptional activation and
FT                   inhibits binding to ABL1."
FT                   /evidence="ECO:0000269|PubMed:15031292"
FT   MUTAGEN         269
FT                   /note="Y->F: No effect on phosphorylation by ABL1."
FT                   /evidence="ECO:0000269|PubMed:15031292"
FT   MUTAGEN         270
FT                   /note="Y->F: No effect on phosphorylation by ABL1."
FT                   /evidence="ECO:0000269|PubMed:15031292"
FT   MUTAGEN         403
FT                   /note="Y->F: No effect on phosphorylation by ABL1."
FT                   /evidence="ECO:0000269|PubMed:15031292"
FT   MUTAGEN         459
FT                   /note="S->A: Loss of PKC-mediated phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:36250347"
FT   MUTAGEN         459
FT                   /note="S->E: Increased activation of the RAC1-ARF6 axis."
FT                   /evidence="ECO:0000269|PubMed:36250347"
FT   MUTAGEN         467
FT                   /note="Y->F: No effect on phosphorylation by ABL1."
FT                   /evidence="ECO:0000269|PubMed:15031292"
FT   MUTAGEN         546
FT                   /note="Y->F: No effect on phosphorylation by ABL1."
FT                   /evidence="ECO:0000269|PubMed:15031292"
FT   MUTAGEN         547
FT                   /note="Y->F: Abrogates phosphorylation and stimulation of
FT                   transcription by ABL1, and increases the interaction with
FT                   RASD1/DEXRAS1."
FT                   /evidence="ECO:0000269|PubMed:15031292,
FT                   ECO:0000269|PubMed:18922798"
FT   MUTAGEN         658
FT                   /note="Y->F: No effect on phosphorylation by ABL1."
FT                   /evidence="ECO:0000269|PubMed:15031292"
FT   MUTAGEN         701
FT                   /note="K->Q: Mimics acetylation; leading to increased
FT                   transcription activator activity; when associated with
FT                   Q-204."
FT                   /evidence="ECO:0000269|PubMed:33938178"
FT   MUTAGEN         701
FT                   /note="K->R: Abolished acetylation by KAT5, leading to
FT                   decreased transcription activator activity; when associated
FT                   with R-204."
FT                   /evidence="ECO:0000269|PubMed:33938178"
FT   CONFLICT        367
FT                   /note="I -> T (in Ref. 4; BAH11532)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        493
FT                   /note="T -> A (in Ref. 4; BAH11532)"
FT                   /evidence="ECO:0000305"
FT   STRAND          259..263
FT                   /evidence="ECO:0007829|PDB:2HO2"
FT   STRAND          268..272
FT                   /evidence="ECO:0007829|PDB:2HO2"
FT   TURN            273..275
FT                   /evidence="ECO:0007829|PDB:2HO2"
FT   STRAND          278..281
FT                   /evidence="ECO:0007829|PDB:2HO2"
FT   STRAND          368..379
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   HELIX           382..385
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   TURN            387..389
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   HELIX           390..401
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   STRAND          421..427
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   STRAND          430..434
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   TURN            436..438
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   STRAND          441..446
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   HELIX           447..449
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   STRAND          452..455
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   STRAND          458..460
FT                   /evidence="ECO:0007829|PDB:3D8F"
FT   STRAND          464..470
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   TURN            472..474
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   STRAND          477..486
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   HELIX           488..504
FT                   /evidence="ECO:0007829|PDB:3D8D"
FT   STRAND          544..554
FT                   /evidence="ECO:0007829|PDB:3DXE"
FT   HELIX           559..571
FT                   /evidence="ECO:0007829|PDB:3DXE"
FT   HELIX           575..577
FT                   /evidence="ECO:0007829|PDB:3DXE"
FT   STRAND          579..585
FT                   /evidence="ECO:0007829|PDB:3DXE"
FT   STRAND          587..594
FT                   /evidence="ECO:0007829|PDB:3DXE"
FT   TURN            595..597
FT                   /evidence="ECO:0007829|PDB:3DXE"
FT   STRAND          600..605
FT                   /evidence="ECO:0007829|PDB:3DXE"
FT   HELIX           606..608
FT                   /evidence="ECO:0007829|PDB:3DXE"
FT   STRAND          609..614
FT                   /evidence="ECO:0007829|PDB:3DXE"
FT   STRAND          620..628
FT                   /evidence="ECO:0007829|PDB:3DXE"
FT   STRAND          631..641
FT                   /evidence="ECO:0007829|PDB:3DXE"
FT   HELIX           644..665
FT                   /evidence="ECO:0007829|PDB:3DXE"
SQ   SEQUENCE   710 AA;  77244 MW;  FD4A2EF7E8D8E884 CRC64;
     MSVPSSLSQS AINANSHGGP ALSLPLPLHA AHNQLLNAKL QATAVGPKDL RSAMGEGGGP
     EPGPANAKWL KEGQNQLRRA ATAHRDQNRN VTLTLAEEAS QEPEMAPLGP KGLIHLYSEL
     ELSAHNAANR GLRGPGLIIS TQEQGPDEGE EKAAGEAEEE EEDDDDEEEE EDLSSPPGLP
     EPLESVEAPP RPQALTDGPR EHSKSASLLF GMRNSAASDE DSSWATLSQG SPSYGSPEDT
     DSFWNPNAFE TDSDLPAGWM RVQDTSGTYY WHIPTGTTQW EPPGRASPSQ GSSPQEESQL
     TWTGFAHGEG FEDGEFWKDE PSDEAPMELG LKEPEEGTLT FPAQSLSPEP LPQEEEKLPP
     RNTNPGIKCF AVRSLGWVEM TEEELAPGRS SVAVNNCIRQ LSYHKNNLHD PMSGGWGEGK
     DLLLQLEDET LKLVEPQSQA LLHAQPIISI RVWGVGRDSG RERDFAYVAR DKLTQMLKCH
     VFRCEAPAKN IATSLHEICS KIMAERRNAR CLVNGLSLDH SKLVDVPFQV EFPAPKNELV
     QKFQVYYLGN VPVAKPVGVD VINGALESVL SSSSREQWTP SHVSVAPATL TILHQQTEAV
     LGECRVRFLS FLAVGRDVHT FAFIMAAGPA SFCCHMFWCE PNAASLSEAV QAACMLRYQK
     CLDARSQAST SCLPAPPAES VARRVGWTVR RGVQSLWGSL KPKRLGAHTP
//
